Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy-Reference-Cited by-同舟云学术

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy

Published:2016-01-11 Issue: Volume:5 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Shiota Masaki,Yokomizo Akira,Eto Masatoshi

Funder

Japan Society for the Promotion of Science

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference23 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Castration-resistant prostate cancer: novel therapeutics pre- or post-taxane administration;Shiota;Curr Cancer Drug Targets,2013

4. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer;Eigl;Clin Cancer Res,2005

5. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer;Fizazi;Anticancer Res,2004

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer;Molecular Biology Reports;2024-01-28

2. External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy;JMA Journal;2022

3. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients;Frontiers in Oncology;2021-11-23

4. Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC;Cancers;2021-11-08

5. Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study;Prostate International;2021-06